Alopecia areata

C Herbert Pratt, Lloyd E King Jr, Andrew G Messenger, Angela M Christiano, John P Sundberg, C Herbert Pratt, Lloyd E King Jr, Andrew G Messenger, Angela M Christiano, John P Sundberg

Abstract

Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. Skin biopsies of affected skin show a lymphocytic infiltrate in and around the bulb or the lower part of the hair follicle in the anagen (hair growth) phase. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata. Genetic studies in patients and mouse models have shown that alopecia areata is a complex, polygenic disease. Several genetic susceptibility loci were identified to be associated with signalling pathways that are important to hair follicle cycling and development. Alopecia areata is usually diagnosed based on clinical manifestations, but dermoscopy and histopathology can be helpful. Alopecia areata is difficult to manage medically, but recent advances in understanding the molecular mechanisms have revealed new treatments and the possibility of remission in the near future.

Conflict of interest statement

Competing interests

L.E.K. is on the scientific advisory committee for the National Alopecia Areata Foundation (NAAF) and Cicatricial Alopecia Research Foundation (CARF). A.M.C. is on the scientific advisory committee for NAAF and is a consultant for Aclaris Therapeutics, Inc. J.P.S. has or has had sponsored research contract with Biocon LLC and the NAAF for preclinical trials using mouse models for alopecia areata, and is on the scientific advisory committee for NAAF and Chairman for CARF. C.H.P. and A.G.M. have no conflicts to disclose.

Figures

Figure 1. Hair cycle
Figure 1. Hair cycle
During the anagen phase (the period when a hair follicle is actively growing), which can vary from a few weeks to several years, epithelial cells in the hair bulb undergo vigorous mitotic activity and differentiate as they move distally to form the hair fiber and its surrounding inner root sheath and inner layer of the outer root sheath. Eventually, epithelial cell division ceases, and the follicle enters the catagen phase, in which the proximal end of the hair shaft keratinizes to form a club-shaped structure, which eventually sheds, and the lower part of the follicle involutes by apoptosis. The telogen phase marks the period between follicular regression and the onset of the next anagen phase (solid arrows). The development of the anagen follicle, which closely replicates embryonic development of the hair follicle, is conventionally divided into six stages (I–VI, with anagen VI representing the fully formed anagen follicle). In most mammals, hair cycles are coordinated in a wave-like fashion across the skin (moult waves), but in humans, follicles cycle independently of their neighbors. In alopecia areata (dashed arrow), anagen VI follicles are precipitated prematurely into telogen phase. Although they are probably able to re-enter anagen phase, the development of the follicle is halted at the anagen III/IV stage,, when they prematurely return to the telogen phase. Truncated cycles may continue if and until disease activity declines, and follicles are able to progress further into the anagen phase.
Figure 2. Breakdown of immune privilege in…
Figure 2. Breakdown of immune privilege in alopecia areata
a) Immune privilege of the hair follicle can be achieved through several strategies including: down regulation of MHC class I and β2 microglobulin, which normally stimulate natural killer (NK) cells; local production of immunosuppressants; expression of immunoinhibitory signals (for example, CD200; also known as OX2 membrane glycoprotein); and repression of intrafollicular antigen-presenting cell (APC), perifollicular NK cell and mast cell functions owing to increased levels of macrophage migration inhibitory factor (MIF). Vasoactive intestinal peptide (VIP), released by perifollicular sensory nerve fibers, is also believed to be an immunoinhibitory neuropeptide that might have a role in immune privilege. b) Late anagen hair follicles in patients with alopecia areata have perifollicular infiltrations of APCs, CD4+ and CD8+ T cells, and abnormal expression of MHC class I and II molecules. CD8+ T cells also infiltrate into the hair follicle root sheaths. Molecules involved in the lymphocyte co-stimulatory cascade are involved in the pathogenesis of alopecia area and provide targets for therapeutic intervention. No inflammatory cells are found in the surrounding of nomal follicles in late anagen phase. INFγ, interferon gamma; IFNγR, interferon gamma receptor; IL2RB, IL2 receptor subunit beta; IL15RA, IL15 receptor subunit alpha; JAK, Janus kinase; NKG2D, NK cell receptor D; NKG2DL, NKG2D ligand; P, phosphorylated; POMC, pro-opiomelanocortin; STAT1, signal transducer and activator of transcription 1; TCR, T cell receptor; TGFB, transforming growth factor beta, VIPR, VIP receptor.
Figure 3. C3H/HeJ mouse model of alopecia…
Figure 3. C3H/HeJ mouse model of alopecia areata
a) Alopecia areata in C3H/HeJ mice is shown (part a). Spontaneous alopecia development in C3H/HeJ mice starts with patchy alopecia areata in the axillary and inguinal regions, which spreads across the ventral skin to the dorsal skin and eventually results in diffuse alopecia. Note that the fine hair of the tail and ears are not involved. Analysis of the hair of C3H/HeJ mice with alopecia areata (parts b–e). The regular sepate or seputulate (ladder-like) pattern of the normal hair medulla (part f and part g) is lost and the hair shaft becomes thin and serpentine (parts b–e). These deformities weaken the hair and result in shaft breakage (parts b–e). Normal hair shafts from an unaffected C3H/HeJ mouse reveal the regular septulate (3 rows) and septate (1 row) cellular pattern within the hair shafts (part f and part g). Parts c, e and g are enlargements of the boxes in parts b, d and f, respectively. Histopathological analysis of skin is shown (parts h–k). Mice with alopecia areata have various degrees of inflammation and follicular dystrophy in and around the anagen hair shafts (parts h–j). A healthy, late anagen stage hair follicle is shown in part k.
Figure 4. Clinical manifestations of alopecia areata
Figure 4. Clinical manifestations of alopecia areata
a) Limited patchy alopecia areata (<50% scalp involvement). b) Extensive patchy alopecia areata (>50% scalp involvement). c) Active patch of alopecia areata showing exclamation point hairs (arrow) and slight skin erythema. d) Alopecia universalis. e) Ophiasis pattern of alopecia areata. f) Sparing of white hairs in alopecia areata. g) Nail pitting and longitudinal striations (trachyonychia) associated with alopecia areata. Part c and part f are reproduced with permission from REF 208, Wiley. Part e is reproduced with permission from REF 209, Springer. Part c and part f are reproduced with permission from Messenger, A. G., Sinclair, R. D., Farrant, P. & de Berker, D. A. R. in Rook’s Textbook of Dermatology 9th edn (eds Griffiths, C., Barker, J., Bleiker, T., Chalmers, R. & Creamer, D.) 89 (Wiley-Blackwell, 2016), Wiley. Part e is reproduced with permission from Bohm, M. in European Handbook of Dermatological Treatments (eds Katsambas, A. D., Lotti, T. M., Dessinioti, C, & D’Erme, A. M.) 45-53 (Springer Berlin Heidelberg, 2015), Springer
Figure 5. Diagnostic tools to validate and…
Figure 5. Diagnostic tools to validate and differentiate alopecia areata
a) Dermoscopy of the skin of patient with alopecia areata. Black arrowheads point to dystrophic, cadaverized and twisted hairs. The asterisk denotes a yellow dot with follicular plugging by keratinaceous debris. White arrows point to short, regrowing miniaturized hairs. b) Plucked exclamation point hairs are characterized by proximal hair shaft narrowing and are always broken; they might show reduced pigmentation. c) Histopathology of a vertical section of a skin biopsy from patch of alopecia areata with very early regrowth of hypopigmented hair. An early anagen hair bulb with vacuolar degeneration (arrows) of epithelial cells around the upper pole of the dermal papilla. d) A horizontal section from a similar area showing lymphocytic infiltrate (arrows) surrounding and infiltrating an anagen hair bulb. Part b is reproduced with permission from REF 208, Wiley. Part c is adopted with permission from REF, Wiley. Part b is reproduced with permission from Messenger, A. G., Sinclair, R. D., Farrant, P. & de Berker, D. A. R. in Rook’s Textbook of Dermatology 9th edn (eds Griffiths, C., Barker, J., Bleiker, T., Chalmers, R. & Creamer, D.) 89 (Wiley-Blackwell, 2016), Wiley. Part c is adapted with permission from Messenger, A. G., Slater, D. N. & Bleehen, S. S. Alopecia areata: alterations in the hair growth cycle and correlation with the follicular pathology. Br. J. Dermatol.114, 337-347 (1986), Wiley

References

    1. McElwee KJ, et al. Comparison of alopecia areata in human and nonhuman mammalian species. Pathobiology : journal of immunopathology, molecular and cellular biology. 1998;66:90–107.
    1. Xing L, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20:1043–1049. doi: 10.1038/nm.3645.
    1. Duvic M, et al. The national alopecia areata registry-update. J Invest Dermat Symp Proc. 2013;16:S53.
    1. Petukhova L, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466:113–117.
    1. Shi Q, et al. Health-Related Quality of Life (HRQoL) in alopecia areata patients-a secondary analysis of the National Alopecia Areata Registry Data. J Invest Dermat Symp Proc. 2013;16:S49–50.
    1. Michie HJ, Jahoda CAB, Oliver RF, Johnson BE. The DEBR rat: an animal model of human alopecia areata. Brit J Dermatol. 1991;125:94–100.
    1. Oliver R, et al. The DEBR rat model for alopecia areata. J Invest Dermatol. 1991;96:97S.
    1. Sundberg JP, Cordy WR, King LE. Alopecia areata in aging C3H/HeJ mice. J Invest Dermatol. 1994;102:847–856.
    1. Jabbari A, et al. Molecular signatures define alopecia areata subtypes and transcriptional biomarkers. EBioMedicine. 2016;7:240–247.
    1. Gip L, Lodin A, Molin L. Alopecia areata. A follow-up investigation of outpatient material. Acta Derm Venereol. 1969;49:180–188.
    1. Walker SA, Rothman S. A statistical study and consideration of endocrine influences. J Invest Dermatol. 1950;14:403–413.
    1. Ikeda T. A new classification of alopecia areata. Dermatologica. 1965;131:421–445.
    1. Ro BI. Alopecia areata in Korea (1982–1994) J Dermatol. 1995;22:858–864.
    1. Safavi K. Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol. 1992;128:702.
    1. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ. Incidence of alopecia areata in Olmstead County, Minnesota 1975–1989. Mayo Clin Proc. 1995;70:628–633.
    1. Mirzoyev SA, Schrum AG, Davis MD, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990–2009. J Invest Dermatol. 2014;134:1141–1142.
    1. Fricke ACV, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397–403.
    1. Whiting DA. Histopathologic features of alopecia areata. Arch Dermatol. 2003;139:1555–1559.
    1. Lundin M, et al. Gender differences in alopecia areata. J Drugs Dermatol. 2014;13:409–413.
    1. Ranawaka RR. An observational study of alopecia areata in Sri Lankan adult patients. Ceylon Med J. 2014;59:128–131.
    1. Messenger AAA. In: Rook’s Textbook of Dermatology. 8. Burns Tony, Breathnach Stephen, Cox Neil, Griffiths Christopher., editors. Chapter 66. Wiley-Blackwell; pp. 31–38.
    2. Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s Textbook of Dermatology. Wiley-Blackwell; 2010. pp. 31–38.
    1. Rocha J, et al. Alopecia areata: a retrospective study of the paediatric dermatology department (2000–2008) Acta Med Port. 2011;24:207–214.
    1. Nanda A, Al-Fouzan AS, Al-Hasawi F. Alopecia areata in children: a clinical profile. Pediatr Dermatol. 2002;19:482–485.
    1. Xiao FL, et al. The epidemiology of childhood alopecia areata in China: a study of 226 patients. Pediatr Dermatol. 2006;23:13–18.
    1. Kakourou T, Karachristou K, Chrousos G. A case series of alopecia areata in children: impact of personal and family history of stress and autoimmunity. J Eur Acad Dermatol Venereol. 2007;21:356–359.
    1. Guzmán-Sánchez DA, Villanueva-Quintero GD, Alfaro N, McMichael A. A clinical study of alopecia areata in Mexico. Int J Dermatol. 2007;46:1308–1310. doi: 10.1111/j.1365-4632.2007.03320.x.
    1. Yang S, et al. The genetic epidemiology of alopecia areata in China. Br J Dermatol. 2004;151:16–23.
    1. Tan E, Tay YK, Giam YC. A clinical study of childhood alopecia in Singapore. Pediatr Dermatol. 2002;19:298–301.
    1. Barsky S, Gigli I. Alopecia areata in twins. Arch Dermatol. 1961;83:224–225.
    1. Bonjean M, Prime A, Avon P. Pelade chez deux jumeaux homozygotes (sic) Lyon Med. 1968;219:1852–1853.
    1. Cole GW, Herzlinger D. Alopecia universalis in identical twins. Int J Dermatol. 1984;23:283.
    1. Hendren S. Identical alopecia areata in identical twins. Arch Dermatol. 1949;60:793–795.
    1. Weidman AI, Zion LS, Mamelok AE. Alopecia areata occurring simultaneously in identical twins. Arch Dermatol. 1956;74:424–426.
    1. Werth VP, White WL, Sanchez MR, Franks AG. Incidence of alopecia areata and lupus erythematosus. Arch Dermatol. 1992;128:368–371.
    1. Insler MS, Helm CJ. Alopecia areata including the cilia and eyebrows of two sisters. Ann Ophthalmol. 1989;21:451–453.
    1. Hordinsky MK, Hallgren H, Nelsen D, Filipovich AH. Familial alopecia areata. HLA antigens and autoimmunity formation in an American family. Arch Dermatol. 1984;120:464–468.
    1. Van der Steen P, et al. The genetic risk for alopecia areata in first degree relatives of severely affected patients. An estimate. Acta Derm Venereol (Stockh) 1992;72:373–375.
    1. Dawn G, Kumar B. Profile of alopecia areata in northern India. Intnatl J Dermatol. 1996;35:22–27.
    1. Barahmani N, et al. Human leukocyte antigen class II alleles are associated with risk of alopecia areata. J Invest Dermatol. 2008;128:240–243.
    1. Betz RC, et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nature Commun. 2015;6:5966. doi: 10.1038/ncomms6966.
    1. Sundberg JP, et al. Major locus on mouse chromosome 17 and minor locus on chromosome 9 are linked with alopecia areata in C3H/HeJ mice. J Invest Dermatol. 2003;120:771–775.
    1. Sundberg JP, Silva KA, Li R, King LE, Cox GA. Adult onset alopecia areata is a complex polygenic trait in the C3H/HeJ mouse model. J Invest Dermatol. 2004;123:294–297.
    1. Chu SY, et al. Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. J Am Acad Dermatol. 2011;65:949–956.
    1. Chen CH, Wang KH, Lin HC, Chung SD. Follow-up study on the relationship between alopecia areata and risk of autoimmune diseases. J Dermatol. 2015;43:228–229.
    1. Garzorz N, et al. Dissecting susceptibility from exogenous triggers: the model of alopecia areata and associated inflammatory skin diseases. J Eur Acad Dermatol Venereol. 2015;29:2429–2435.
    1. Lee NR, et al. Differences in comorbidity profiles between early-onset and late-onset alopecia areata patients: a retrospective study of 871 Korean patients. Ann Dermatol. 2014;26:722–726.
    1. Mohan GC, Silverberg JI. Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2015;151:522–528.
    1. Chen CH, et al. Association between herpes zoster and alopecia areata: a population-based study. J Dermatol. 2015;42:824–825.
    1. Diaz-Angulo S, Lopez-Hoyos M, Munoz-Cacho P, Lopez-Escobar M, Gonzalez-Lopez MA. High prevalence of thyroid autoimmunity in patients with alopecia areata and vitiligo: a controlled study. Australas J Dermatol. 2015;56:142–143.
    1. Kurtipek GS, Cihan FG, Demirbas SE, Ataseven A. The frequency of autoimmune thyroid disease in alopecia areata and vitiligo patients. Biomed Res Int. 2015;2015 Article ID 435947, 435944.
    1. Petukhova L, Christiano AM. The genetic architecture of alopecia areata. J Invest Dermatol Symp Proc. 2013;16:S16–S22.
    1. Kavak A, Baykal C, Ozarmagan G, Akar U. HLA and alopecia areata. Int J Dermatol. 2000;39:589–592.
    1. Hordinsky MK. Overview of alopecia areata. J Investig Dermatol Symp Proc. 2013;16:S13–15.
    1. Colombe BW, Lou CD, Price VH. The genetic basis of alopecia areata: HLA associations with patchy alopecia areata versus alopecia totalis and alopecia universalis. J Invest Dermatol Symp Proc. 1999;4:216–219.
    1. Gough SC, Simmonds MJ. The HLA region and autoimmune disease: associations and mechanisms of action. Curr Genomics. 2007;8:453–465. doi: 10.2174/138920207783591690.
    1. Petukhova L, Christiano AM. Functional interpretation of genome-wide association study evidence in alopecia areata. J Invest Dermatol. 2016;136:314–317.
    1. Carroll J, McElwee KJ, King LE, Byrne MC, Sundberg JP. Gene array profiling and immunomodulation studies define a cell mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans. J Invest Dermatol. 2002;119:392–402.
    1. McPhee CG, et al. Gene expression studies identify Cxcr3 and its ligands, Cxcl9, Cxcl10, and Cxcl11 in the pathogenesis of alopecia areata in the mouse. J Invest Dermatol. 2012;132:1736–1738.
    1. Fischer J, et al. Genome-wide analysis of copy number variants in alopecia areata in a Central European cohort reveals association with MCHR2. Exp Dermatol. 2016 doi: 10.1111/exd.13123. Epub ahead of print.
    1. Rice RH, et al. Differentiating inbred mouse strains from each other and those with single gene mutations using hair proteomics. PLos One. 2012;7:e51956.
    1. Rice RH, et al. Distinguishing mouse strains by proteomic analysis of pelage hair. J Invest Dermatol. 2009;129:2120–2125.
    1. Sundberg JP, et al. Crisp1 and alopecia areata in C3H/HeJ mice. Exp Mol Pathol. 2014;97:525–528.
    1. Eckert J, Church RE, Ebling FJ. The pathogenesis of alopecia areata. Br J Dermatol. 1968;80:203–210.
    1. Messenger AG, Slater DN, Bleehen SS. Alopecia areata: alterations in the hair growth cycle and correlation with the follicular pathology. Br J Dermatol. 1986;114:337–347.
    1. VanScott EJ. Morphologic changes in pilosebaceous units and anagen hairs in alopecia areata. J Invest Dermatol. 1958;31:35–43.
    1. Chase HB, Rauch H, Smith VW. Critical stages of hair development and pigmentation in the mouse. Physiol Zool. 1951;24:1–10.
    1. Thies W. Vergleichende histologische Untersuchungen bei Alopecia areata und narbig-atrophisierenden. Archiv Für Klinische Und Experimentelle Dermatologie. 1966;227:541–549.
    1. Messenger AG, Bleehen SS. Alopecia areata: light and electron microscopic pathology of the regrowing white hair. Br J Dermatol. 1984;110:155–162.
    1. Paus R, Slominski A, Czarnetzki BM. Is alopecia areata an autoimmune-response against melanogenesis-related proteins exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med. 1993;66:541–554.
    1. Tharumanathan S. Understanding the biological mechanism of alopecia areata. Am J Dermatol Venereol. 2015;4:1–4. doi: 10.5923/j.ajdv.20150401.01.
    1. Paus R, Bertolini M. The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives. J Investig Dermatol Symp Proc. 2013;16:S25–27.
    1. Paus R, Nickoloff BJ, Ito T. A “hairy” privilege. Trends Immunol. 2005;26:32–40.
    1. Meyer KC, et al. Evidence that the bulge region is a site of relative immune privilege in human hair follicles. Br J Dermatol. 2008;159:1077–1085.
    1. Ito T, Meyer KC, Ito N, Paus R. Immune privilege and the skin. Curr Dir Autoimmun. 2008;10:27–52.
    1. Trautman S, Thompson M, Roberts J, Thompson CT. Melanocytes: a possible autoimmune target in alopecia areata. J Am Acad Dermatol. 2009;61:529–530. doi: 10.1016/j.jaad.2009.01.017.
    1. Ito T, et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol. 2008;128:1196–1206.
    1. Bertolini M, et al. Vasoactive intestinal peptide, whose receptor-mediated signalling may be defective in alopecia areata, provides protection from hair follicle immune privilege collapse. Br J Dermatol. 2016;175:531–541.
    1. Finner AM. Alopecia areata: Clinical presentation, diagnosis, and unusual cases. Dermatol Therapy. 2011;24:348–354.
    1. Messenger AG, Bleehen SS. Expression of HLA-DR by anagen hair follicles in alopecia areata. J Invest Dermatol. 1985;85:569–572.
    1. Paus R, Slominski A, Czarnetzki BM. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med. 1993;66:541–554.
    1. Gilhar A, et al. Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdcscid mice. J Invest Dermatol. 2001;117:1357–1362.
    1. Erb U, Freyschmidt-Paul P, Zöller M. Tolerance induction by hair-specific keratins in murine alopecia areata. J Leukoc Biol. 2013;94:845–857.
    1. Wang EH, et al. Identification of autoantigen epitopes in alopecia areata. J Invest Dermatol. 2016;136:1617–1626. doi: 10.1016/j.jid.2016.04.004.
    1. Alzolibani AA. Preferential recognition of hydroxyl radical-modified superoxide dismutase by circulating autoantibodies in patients with alopecia areata. Ann Dermatol. 2014;26:576–583.
    1. Kalkan G, et al. Relationship between manganese superoxide dismutase (MnSODAla-9Val) and glutathione peroxidase (GPx1 Pro 197 Leu) gene polymorphisms and alopecia areata. Int J Exp Med. 2015;8:21533–21540.
    1. Fattah NSA, Ebrahim A, Okda ESE. Lipid peroxidation/antioxidant activity in patients with alopecia areata. J Eur Acad Dermatol Venereol. 2011;25:403–408.
    1. Mijailović B, Mladenović T, Hrnjak M, Karadaglić D, Nikolić B. Contact thermometry of lesions in alopecia areata. Vojnosanit Pregl. 1997;54:31–33.
    1. Skoutelis A, Freinkel RK, Kaufman DS, Leibovich SJ. Angiogenic activity is defective in monocytes from patients with alopecia universalis. J Invest Dermatol. 1990;95:139–143.
    1. Popchristov P, Konstantinov A, Obreshkova E. The blood vessels of the scalp in patients with alopecia areata before and after corticosteroid therapy. Br J Dermatol. 1968;80:753–757.
    1. Karaman S, et al. Decline of lymphatic vessel density and function in murine skin during aging. Angiogenesis. 2015;18:489–498.
    1. Sundberg JP, et al. Dermal lymphatic dilation in a mouse model of alopecia areata. Exp Mol Pathol. 2016;100:332–336.
    1. Sundberg JP, Elson CO, Bedigian H, Birkenmeier EH. Spontaneous, heritable colitis in a new substrain of C3H/HeJ mice. Gastroenterology. 1994;107:1726–1735.
    1. Safina DD, Abdulkhakov RA, Abdulkhakov SR, Odintsova AK, Cheremina NA. Clinical case of a combination of ulcerative colitis and alopecia areata. Eksp Klin Gastroenterol. 2013;2013:92–96.
    1. McElwee KJ, Boggess D, King LE, Sundberg JP. Experimental induction of alopecia areata-like hair loss in C3H/HeJ mice using full-thickness skin grafts. J Invest Dermatol. 1998;111:797–803.
    1. McElwee KJ, et al. Dietary soy oil content and soy derived phytoestrogen genistein increase resistance to alopecia areata onset in C3H/HeJ mice. Exp Dermatol. 2003;12:30–36.
    1. Chu CH, Cheng YP, Chan JYL. Alopecia areata after vaccination: recurrence with rechallenge. Pediatr Dermatol. 2016;33:e218–219.
    1. Wise R, Kiminyo K, Salive M. Hair loss after routine vaccination. JAMA. 1997;278:1176–1178.
    1. Sánchez-Ramón S, Gil J, Cianchetta-Sívori M, Fernández-Cruz E. Alopecia universalis in an adult after routine tetanus toxoid vaccine. Med Clin (Barc) 2011;136:318.
    1. Lai YC, Yew YW. Severe autoimmune adverse events post herpes zoster vaccine: A case-control study of adverse events in a national database. J Drugs Dermatol. 2015;14:681–684.
    1. Geier DA, Geier MR. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events. Clin Rheumatol. 2015;34:1225–1231.
    1. Ito T, Tokura Y. Alopecia areata triggered or exacerbated by swine flu virus infection. J Dermatol. 2012;39:863–864. doi: 10.1111/j.1346-8138.2011.01437.
    1. Sundberg JP, et al. Recombinant human hepatitis B vaccine initiating alopecia areata: testing the hypothesis using the C3H/HeJ mouse model. Vet Dermatol. 2009;20:99–104.
    1. Sundberg JP, McElwee KJ, Brehm MA, Su L, King LE. Animal models for alopecia areata: what and where? J Invest Dermatol Symp Proc. 2015;17:23–26.
    1. Gilhar A, Schrum AG, Etzioni A, Waldman H, Paus R. Alopecia areata: animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies. Autoimmun Rev. 2016;15:726–735.
    1. Sundberg JP, Booth CJ, Nanney LB, Fleckman P, King LE. In: Comparative anatomy and histology. A mouse, rat, and human atlas. Treuting P, et al., editors. Academic Press; 2017. in press.
    1. Sundberg JP, et al. In: McKee’s Pathology of the Skin. Calonje E, Brenn T, Lazar A, McKee PH, editors. Elsevier; in press.
    1. Freyschmidt-Paul P, et al. Treatment of alopecia areata in C3H/HeJ mice with the topical immunosuppressant FK506 (Tacrolimus) Eur J Dermatol. 2001;11:405–409.
    1. Sun J, Silva KA, McElwee KJ, King LE, Sundberg JP. The C3H/HeJ mouse and DEBR rat models for alopecia areata: preclinical drug screening tools. Exp Dermatol. 2008;17:793–805.
    1. Harries MJ, Sun J, Paus R, King LE. Management of alopecia areata. Brit Med J. 2010;341:c3671.
    1. McElwee K, Boggess D, Miller J, King L, Sundberg J. Spontaneous alopecia areata-like hair loss in one congenic and seven inbred laboratory mouse strains. J Invest Dermatol Symp Proc. 1999;4:202–206.
    1. Sundberg JP, et al. Mouse alopecia areata and heart disease: know your mouse! J Invest Dermatol. 2014;134:279–281.
    1. Poltorak A, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085–2088.
    1. Berning AK, Eicher EM, Paul WE, Scher I. Mapping of the X-linked immune deficiency mutation (xid) of CBA/N mice. J Immunol. 1980;124:1875–1877.
    1. King LE, McElwee KJ, Sundberg JP. In: Dermatologic Immunity: Current Directions in Autoimmunity. Nickoloff BJ, Nestle FO, editors. Vol. 10. Karger; 2008. pp. 280–312.
    1. Alli R, Nguyen P, Boyd K, Sundberg JP, Geiger TL. A mouse model of clonal CD8+ T lymphocyte-mediated alopecia areata progressing to alopecia universalis. J Immunol. 2012;188:477–486.
    1. McElwee KJ, et al. Alopecia areata in C3H/HeJ mice involves leucocyte-mediated root sheath disruption in advance of overt hair loss. Vet Pathol. 2003;40:643–650.
    1. Silva KA, Sundberg JP. Surgical methods for full thickness skin grafts to induce alopecia areata in C3H/HeJ mice. Comp Med. 2013;63:392–397.
    1. McElwee KJ, et al. Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(-) cells promote systemic alopecia areata and CD4(+)/CD25(+) cells blockade disease onset in the C3H/HeJ mouse model. J Invest Dermatol. 2005;124:947–957.
    1. Gilhar A, et al. Autoimmune disease induction in a healthy human organ: a humanized mouse model of alopecia areata. J Invest Dermatol. 2013;133:844–847.
    1. Restrepo R, Calonje E. In: McKee’s Pathology of the Skin. Calonje E, Brenn T, Lazar A, McKee PH, editors. Vol. 22. Elsevier; 2012. pp. 967–1050.
    1. Messenger AG, Sinclair RD, Farrant P, Berker DARd. In: Rook’s Textbook of Dermatology. Griffiths CEM, et al., editors. Ch. 89. John Wiley & Sons Ltd; 2016.
    1. McElwee KJ, Silva K, Beamer WG, King LE, Sundberg JP. Melanocyte and gonad activity as potential modifying factors in C3H/HeJ mouse alopecia areata. Exp Dermatol. 2001;10:420–429.
    1. Gandhi V, Baruah MC, Bhattacharaya SN. Nail changes in alopecia areata: incidence and pattern. Indian J Dermatol Venereol Leprol. 2003;69:114–115.
    1. Kasumagic-Halilovic E, Prohic A. Nail changes in alopecia areata: frequency and clinical presentation. J Eur Acad Dermatol Venereol. 2009;23:240–241. doi: 10.1111/j.1468-3083.2008.02830.x.
    1. Sharma VK, Dawn G, Muralidhar S, Kumar B. Nail changes in 1000 Indian patients with alopecia areata. Eur J Acad Dermatol Venereol. 1998;10:189–191.
    1. Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol. 2006;55:438–441.
    1. Spek FBDW-vd, Oranje AP, Raeymaecker DMD, Peereboom-Wynia JD. Juvenile versus maturity-onset alopecia areata--a comparative retrospective clinical study. Clin Exp Dermatol. 1989;14:429–433.
    1. Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in Northern India. Int J Dermatol. 1996;35:22–27.
    1. Tan E, Tay YK, Goh CL, Giam YC. The pattern and profile of alopecia areata in Singapore - a study of 219 Asians. Int J Dermatol. 2002;41:748–753.
    1. Goh C, Finkel M, Christos PJ, Sinha AA. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol. 2006;20:1055–1060.
    1. Olsen EA, et al. Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51:440–447.
    1. Jang YH, et al. Alopecia areata progression index, a scoring system for evaluating overall hair loss activity in alopecia areata patients with pigmented hair: a development and reliability assessment. Dermatol. 2016;232:143–149.
    1. Mubki T, Rudnicka L, Olszewska M, Shapiro J. Evaluation, diagnosis of the hair loss patient: part II, Trichoscopic and laboratory evaluations. J Am Acad Dermatol. 2014;71:431.e431–431.e411.
    1. Zlotogorski A, Panteleyev AA, Aita VM, Christiano AM. Clinical and molecular diagnostic criteria of congenital atrichia with papular lesions. J Invest Dermatol. 2002;118:887–890.
    1. Miller J, et al. Atrichia caused by mutations in the vitamin D receptor gene is a phenocopy of generalized atrichia caused by mutations in the hairless gene. J Invest Dermatol. 2001;117:612–617.
    1. Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database Syst Rev. 2008;16:CD004413.
    1. Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166:916–926.
    1. Charuwichitratana S, Wattanakrai P, Tanrattanakorn S. Randomized double-blind placebo-controlled trial in the treatment of alopecia areata with 0.25% desoximetasone cream. Arch Dermatol. 2000;136:1276–1277.
    1. Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol. 2003;49:96–98.
    1. Tosti A, Iorizzo M, Botta GL, Milani M. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol. 2006;20:1243–1247.
    1. Solomon IL, Green OC. Monilethrix: its occurrence in seven generations, with one case that responded to endocrine therapy. N E J Med. 1963;269:1279–1282.
    1. Kubeyinje EP. Intralesional triamcinolone acetonide in alopecia areata amongst 62 Saudi Arabs. East African Med J. 1994;71:674–675.
    1. Fuentes-Duculan J, et al. Biomarkers of alopecia areata disease activity and response to corticosteroid treatment. Exp Dermatol. 2016;25:282–286.
    1. Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol. 1992;128:1467–1473.
    1. Sharma VK, Gupta S. Twice weekly 5 mg dexamethasone oral pulse in the treatment of extensive alopecia areata. J Dermatol. 1999;26:562–565.
    1. Nakajima T, Inui S, Itami S. Pulse corticosteroid therapy for alopecia areata: study of 139 patients. Dermatol. 2007;215:320–324.
    1. Yang CC, et al. Early intervention with high-dose steroid pulse therapy prolongs disease-free interval of severe alopecia areata: a retrospective study. Ann Dermatol. 2013;25:471–474.
    1. Kar BR, Handa S, Dogra S, Kumar B. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol. 2005;52:287–290.
    1. Happle R. Antigenic competition as a therapeutic concept for alopecia areata. Arch Dermatol Res. 1980;267:109–114.
    1. Bröcker EB, Echternacht-Happle K, Hamm H, Happle R. Abnormal expression of class I and class II major histocompatibility antigens in alopecia areata: modulation by topical immunotherapy. J Invest Dermatol. 1987;88:564–568.
    1. Hoffmann R, et al. Growth factor mRNA in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. Acta Derm Venereol. 1996;76:17–20.
    1. Marhaba R, et al. The importance of myeloid-derived suppressor cells in the regulation of autoimmune effector cells by a chronic contact eczema. J Immunol. 2007;179:5071–5081.
    1. Rokhsar CK, Shupack JL, Vafai JJ, Washenik K. Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol. 1998;39:751–761.
    1. Van der Steen PHM, Van Baar HMJ, Happle R, Boezeman JBM, Perret CM. Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol. 1991;24:227–230.
    1. Gordon PM, Aldrige RD, McVittie E, Hunter JA. Topical diphencyprone for alopecia areata: evaluation of 48 cases after 30 months’ follow-up. Br J Dermatol. 1996;134:869–871.
    1. Wiseman MC, Shapiro J, MacDonald N, Lui H. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol. 2001;137:1063–1068.
    1. Hull SM, Pepall L, Cunliffe WJ. Alopecia areata in children: response to treatment with diphencyprone. Br J Dermatol. 1991;125:164–168.
    1. Schuttelaar ML, et al. Alopecia areata in children: treatment with diphencyprone. Br J Dermatol. 1996;135:581–585.
    1. Tosti A, Guidetti MS, Bardazzi F, Misciali C. Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis. J Am Acad Dermatol. 1996;35:199–201.
    1. Tosti A, Guerra L, Bardazzi F. Contact urticaria during topical immunotherapy. Contact Dermatitis. 1989;21:196–197.
    1. MacDonald-Hull SP, Cotterill JA, Norris JF. Vitiligo following diphencyprone dermatitis. Br J Dermatol. 1989;120:323.
    1. Joly P. The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. J Am Acad Dermatol. 2006;55:632–636.
    1. Hammerschmidt M, Brenner FM. Efficacy and safety of methotrexate in alopecia areata. An Bras Dermatol. 2014;89:729–734.
    1. Anuset D, Perceau G, Bernard P, Reguiai Z. Efficacy and safety of methotrexate combined with low- to moderate-dose corticosteroids for severe alopecia areata. Dermatology. 2016;232:242–248.
    1. Shapiro J, Lui H, Tron V, Ho V. Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata. J Am Acad Dermatol. 1997;36:114–117.
    1. Price VH, Willey A, Chen BK. Topical tacrolimus in alopecia areata. J Am Acad Dermatol. 2005;52:138–139.
    1. Strober BE, et al. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol. 2005;52:1082–1084.
    1. Ferran M, Calvet J, Almirall M, Pujol RM, Maymó J. Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-α blocker agents: Report of five cases and review of the literature. J Eur Acad Dermatol Venereol. 2011;25:479–484.
    1. Tauber M, et al. Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol. 2014;70:1146–1149.
    1. Price VH, et al. Subcutaneous efalizumab is not effective in the treatment of alopecia areata. J Am Acad Dermatol. 2008;58:395–402.
    1. Strober BE, et al. Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study. Arch Dermatol. 2009;145:262–266.
    1. Byun JW, Moon JH, Bang CY, Shin J, Choi GS. Effectiveness of 308-nm excimer laser therapy in treating alopecia areata, determined by examining the treated sides of selected alopecic patches. Dermatology. 2015;231:70–76.
    1. Mlacker S, et al. A review on laser and light-based therapies for alopecia areata. J Cosmet Dermatol. 2016 Epub ahead of print.
    1. King LE, Silva KA, Kennedy VE, Sundberg JP. Lack of response to laser comb in spontaneous and graft-induced alopecia areata in C3H/HeJ mice. J Invest Dermatol. 2014;134:264–266.
    1. Claudy AL, Gagnaire D. PUVA treatment of alopecia areata. Arch Dermatol. 1983;119:975–978.
    1. Lassus A, Eskelinen A, Johansson E. Treatment of alopecia areata with three different PUVA modalities. Photodermatol. 1984;1:141–144.
    1. Mitchell AJ, Douglass MC. Topical photochemotherapy for alopecia areata. J Am Acad Dermatol. 1985;12:644–649.
    1. Taylor CR, Hawk JL. PUVA treatment of alopecia areata partialis, totalis and universalis: audit of 10 years’ experience at St John’s Institute of Dermatology. Br J Dermatol. 1995;133:914–918.
    1. Healy E, Rogers S. PUVA treatment for alopecia areata--Does it work? A retrospective review of 102 cases. Br J Dermatol. 1993;129:42–44.
    1. Hunt N, McHale S. The psychological impact of alopecia. Brit Med J. 2005;331:951–953.
    1. Bilgiç Ö, et al. Psychiatric symptomatology and health-related quality of life in children and adolescents with alopecia areata. J Eur Acad Dermatol Venereol. 2014;28:1463–1468. doi: 10.1111/jdv.12315.
    1. Karimkhani C, et al. Global burden of skin disease as reflected in Cochrane Database of Systematic Reviews. JAMA Dermatol. 2014;150:945–951.
    1. Rencz F, et al. Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br J Dermatol. 2016 doi: 10.1111/bjd.14497. Epub ahead of print.
    1. Liu LY, King BA, Craiglow BG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review. J Am Acad Dermatol. 2016;75:806–812.
    1. Cartwright T, Endean N, Porter A. Illness perceptions, coping and quality of life in patients with alopecia. Br J Dermatol. 2009;160:1034–1039. doi: 10.1111/j.1365-2133.2008.09014.
    1. Lebwohl M, Heymann W, Berth-Jones J, Coulson I. Comprehensive Therapeutic Strategies (Expert Consult - Online and Print) 4. Elsevier; 2014.
    1. Sundberg JP, McElwee KJ, Carroll J, King LEJ. Hypothesis testing: CTLA4 costimulatory pathways critical in pathogenesis of human and mouse alopecia areata. J Invest Dermatol. 2011;131:2323–2324.
    1. John KKG, et al. Genetic variants in CTLA4 are strongly associated with alopecia areata. J Invest Dermatol. 2011;131:1169–1172.
    1. Ghoreishi M, Martinka M, Dutz JP. Type 1 interferon signature in the scalp lesions of alopecia areata. Br J Dermatol. 2010;163:57–62.
    1. Subramanya RD, Coda AB, Sinha AA. Transcriptional profiling in alopecia areata defines immune and cell cycle control related genes within disease-specific signatures. Genomics. 2010;96:146–153.
    1. Dai Z, et al. CXCR3 blockade inhibits T cell migration into the skin and prevents development of alopecia areata. J Immunol. 2016 Epub ahead of print.
    1. Guttman-Yassky E, et al. Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism. J Allergy Clin Immunol. 2016;137:301–304.
    1. Lebwohl M. . 2016 .
    1. Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134:2988–2990.
    1. Dhayalan A, King BA. Tofacitinib citrate for the treatment of nail dystrophy associated with alopecia universalis. JAMA Dermatol. 2016;152:492–493.
    1. Gupta AK, Carviel JL, Abramovits W. Efficacy of tofacitinib in treatment of alopecia universalis in two patients. J Eur Acad Dermatol Venereol. 2016 Epub ahead of print.
    1. Crispin MK, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1:e89776.
    1. Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. J Am Acad Dermatol. 2016 Epub ahead of print.
    1. Pieri L, Guglielmelli P, Vannucchi AM. Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Am J Hematol. 2015;90:82–83.
    1. Mackay-Wiggan J, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1:e89790.
    1. Jabbari A, et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor Baricitinib. EBioMedicine. 2015;2:351–355.
    1. Anzengruber F, et al. Transient efficacy of tofacitinib in alopecia areata universalis. Case Rep Dermatol. 2016;8:102–106.
    1. Li Y, et al. Hair regrowth in alopecia areata patients following stem cell educator therapy. BMC Medicine. 2015;13:87.
    1. Sperling LC, Cowper SE, Knopp EA. An atlas of hair pathology with clinical correlations. 2. Informa Healthcare; 2014.
    1. Navarini AA, Nobbe S, Trüeb RM. Marie Antoinette syndrome. Arch Dermatol. 2009;145:656. doi: 10.1001/archdermatol.2009.51.
    1. Forstbauer LM, et al. Genome-wide pooling approach identifies SPATA5 as a new susceptibility locus for alopecia areata. Eur J Hum Genet. 2012;20:326–332. doi: 10.1038/ejhg.2011.185.
    1. Jagielska D, et al. Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance. J Invest Dermatol. 2012;132:2192–2197. doi: 10.1038/jid.2012.129.

Source: PubMed

3
購読する